Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
Neurogene Inc. (NGNE)
Company Research
Source: Yahoo! Finance
Plan to present interim data on pediatric and adolescent/adult cohorts from Phase 1/2 trial in mid-2026 Early commercial-readiness activities underway Neurogene to present at J.P. Morgan Healthcare Conference on January 14 at 7:30 a.m. PT NEW YORK, January 12, 2026 BUSINESS WIRE )--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for multiple value-creating catalysts anticipated in 2026. "We are pleased to share that multiple participants have been dosed in our Embolden registrational trial of NGN-401 gene therapy for Rett syndrome, an important step toward completing dosing in the second quarter," stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "We continue to track the progress of the participants in our Phas
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.MarketBeat
- Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett SyndromeBusiness Wire
- Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
NGNE
Earnings
- 11/13/25 - Beat
NGNE
Sec Filings
- 1/12/26 - Form 8-K
- 12/15/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- NGNE's page on the SEC website